A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer

Conclusions An MTD for the combination was not established. Cabozantinib and gemcitabine appear impractical for further development due to DLT at low doses and continuing toxicities with ongoing therapy. Acknowledging the small sample size, responses were seen suggesting further investigation of c-Met inhibition in PDAC may be warranted.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research